Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood ...

Though more research is needed to understand who might benefit from GLP-1 agonists for addiction, early studies suggest that the approach holds promise.

The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker ...

Unlike other slimming injections, the jab manufactured by US pharmaceutical giant Eli Lilly not only suppresses the appetite ...

British patients with obesity undergoing hip and knee replacements had less of a need for subsequent revision when, after surgery, they lost weight by using medications such as GLP-1 receptor agonists ...

Conagra and General Mills are among the food companies offering special options for people on GLP-1 drugs, but the products ...

A doctor from the University of Palermo in Italy has published a case study of an adult cocaine user who experienced reduced withdrawal symptoms when given GLP-1 therapy. In the case study published ...

Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders ...

As GLP-1 medications such as Ozempic, Mounjaro and Wegovy rise in popularity, so do concerns over their side effects.

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporte ...

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive ...